Information Provided By:
Fly News Breaks for August 8, 2019
Aug 8, 2019 | 07:23 EDT
H.C. Wainwright analyst Ed Arce downgraded Organovo Holdings to Neutral from Buy without a price target. To support the range of possible strategic options under consideration, the company is implementing a restructuring plan to significantly reduce expenses, including suspending development of its lead liver therapeutic tissue program, Arce tells investors in a research note. The analyst cites the "inherent uncertainty of this process and the ultimate outcome" for his downgrade to Neutral.
News For ONVO From the Last 2 Days
There are no results for your query ONVO